Gene Therapy Program | University of Pennsylvania

gtp.med.upenn.edu

Dedicated to discovery + translational research and led by Dr James Wilson, the Gene Therapy Program at the University of Pennsylvania focuses on the development of next-generation gene transfer vectors and their application in the treatment of a variety of acquired and inherited diseases.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Cell and Gene Therapy

AEGLEA BIOTHERAPEUTICS ANNOUNCES LEADERSHIP TRANSITION AND CORPORATE RESTRUCTURING

Aeglea BioTherapeutics, Inc. | August 25, 2022

news image

Aeglea BioTherapeutics, Inc. a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today announced a leadership transition and corporate restructuring to focus resources on AGLE-177 in development for patients living with Homocystinuria. The restructuring has further reduced the headcount of the Company resulting in an approximately 25% reduction year-to-date. The Company also plans to r...

Read More

LIMINAL BIOSCIENCES EXPANDS R&D PIPELINE WITH NOVEL PRECLINICAL PROGRAM FOR EOSINOPHILIC-RELATED DISEASES

Liminal BioSciences Inc. | July 20, 2020

news image

Liminal BioSciences Inc. (Nasdaq: LMNL) (TSX: LMNL) ("Liminal BioSciences" or the "Company"), a clinical-stage biopharmaceutical company, announced today that it has acquired all of the issued and outstanding shares in the capital of Fairhaven Pharmaceuticals Inc. ("Fairhaven"), thus acquiring a preclinical research program of small molecule antagonists. Investigational therapies developed in this program target a key chemoattractant and activator of eosinophils, wh...

Read More

EPIGENTEK LAUNCHED FIRST-OF-ITS-KIND TOOLS TO DETECT SARS-COV-2-TARGETED FURIN ACTIVITY AND SCREEN FOR INHIBITORS AGAINST COVID-19

EpiGentek | July 10, 2020

news image

New York-based biotechnology firm EpiGentek has released a series of SARS-CoV-2 research assays in combatting the ongoing COVID-19 pandemic. The two kits focus on studies of SARS-CoV-2 targeted furin or proprotein convertase (PC) cleavage activity. These first-of-its-kind tools can be used to rapidly detect SARS-CoV-2 targeted PC and facilitated proteases using biological samples as well as screen for inhibitors of these enzymes that cleave SARS-CoV-2 proteins. Subsequent implications can be the...

Read More

Cell and Gene Therapy

MEKONOS RAISES $4.6M FINANCING ROUND FOR TARGETED EX VIVO GENE ENGINEERING

Mekonos | November 24, 2020

news image

Mekonos, a biotech organization launching the first-of-its kind system-on-a-chip (SoC) for focused ex vivo gene engineering, today reported it has finished a $4.6 million financing round. Mekonos will utilize the new funding to quicken the SoC stage for its current and new ad organizations. The SoC stage, with IP from Stanford University, is a breakthrough that allows for molecular delivery in gene editing and synthetic biology. The stage is versatile over all cell types and has demonstrated to ...

Read More
news image

Cell and Gene Therapy

AEGLEA BIOTHERAPEUTICS ANNOUNCES LEADERSHIP TRANSITION AND CORPORATE RESTRUCTURING

Aeglea BioTherapeutics, Inc. | August 25, 2022

Aeglea BioTherapeutics, Inc. a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today announced a leadership transition and corporate restructuring to focus resources on AGLE-177 in development for patients living with Homocystinuria. The restructuring has further reduced the headcount of the Company resulting in an approximately 25% reduction year-to-date. The Company also plans to r...

Read More
news image

LIMINAL BIOSCIENCES EXPANDS R&D PIPELINE WITH NOVEL PRECLINICAL PROGRAM FOR EOSINOPHILIC-RELATED DISEASES

Liminal BioSciences Inc. | July 20, 2020

Liminal BioSciences Inc. (Nasdaq: LMNL) (TSX: LMNL) ("Liminal BioSciences" or the "Company"), a clinical-stage biopharmaceutical company, announced today that it has acquired all of the issued and outstanding shares in the capital of Fairhaven Pharmaceuticals Inc. ("Fairhaven"), thus acquiring a preclinical research program of small molecule antagonists. Investigational therapies developed in this program target a key chemoattractant and activator of eosinophils, wh...

Read More
news image

EPIGENTEK LAUNCHED FIRST-OF-ITS-KIND TOOLS TO DETECT SARS-COV-2-TARGETED FURIN ACTIVITY AND SCREEN FOR INHIBITORS AGAINST COVID-19

EpiGentek | July 10, 2020

New York-based biotechnology firm EpiGentek has released a series of SARS-CoV-2 research assays in combatting the ongoing COVID-19 pandemic. The two kits focus on studies of SARS-CoV-2 targeted furin or proprotein convertase (PC) cleavage activity. These first-of-its-kind tools can be used to rapidly detect SARS-CoV-2 targeted PC and facilitated proteases using biological samples as well as screen for inhibitors of these enzymes that cleave SARS-CoV-2 proteins. Subsequent implications can be the...

Read More
news image

Cell and Gene Therapy

MEKONOS RAISES $4.6M FINANCING ROUND FOR TARGETED EX VIVO GENE ENGINEERING

Mekonos | November 24, 2020

Mekonos, a biotech organization launching the first-of-its kind system-on-a-chip (SoC) for focused ex vivo gene engineering, today reported it has finished a $4.6 million financing round. Mekonos will utilize the new funding to quicken the SoC stage for its current and new ad organizations. The SoC stage, with IP from Stanford University, is a breakthrough that allows for molecular delivery in gene editing and synthetic biology. The stage is versatile over all cell types and has demonstrated to ...

Read More